China Sunsine Chemical Holdings Ltd. announced on Apr, 30 2026 that it achieved a record first-quarter sales volume of 60,916 tonnes for the three months ended Mar, 31 2026, up 15% from a year earlier.

Despite the higher volumes, the average selling price declined 7% year on year, reflecting pre-agreed lower contract rates that limited the company’s ability to fully pass on rising raw-material costs. Consequently, revenue grew 6% while the gross profit margin narrowed by 2.7 percentage points to 21.4%. Net profit came in at 69.5 million.

The company said it will continue to pursue a strategy of “sales and production equilibrium,” employ flexible pricing and focus on productivity and cost control to sustain profitability amid challenging market conditions.

Progress on capacity expansion remains on track. Commercial output has started at the second phase of a 40,000-tonne-per-annum continuous MBT solvent line at the Henghsun plant. A separate 20,000-tonne-per-annum MBT project in Weifang is set for trial runs in May 2026, with full commercial production targeted by year-end. Conversion of a TBBS workshop to a CBS unit at the Shandong plant is expected to begin trial operations in the first half of 2026.

These initiatives are projected to lift China Sunsine’s total annual production capacity to 272,000 tonnes by the end of 2026, compared with 254,000 tonnes at end-2025.